Skip to main content
padlock icon - secure page this page is secure

Research Update: Misoprostol—Is More Research Needed?

Buy Article:

$24.00 + tax (Refund Policy)

Misoprostol (Cytotec) is a synthetic prostaglandin E1 analogue that was designed for the prevention and treatment of peptic ulcer associated with the use of nonsteroidal anti-inflammatory drugs. In obstetrics, misoprostol has been administered for induction of first and second trimester abortion, for induction of labor in the third trimester, and to control postpartum hemorrhage. None of these uses has been approved by the Food and Drug Administration. Nevertheless, misoprostol is widely used in the United States and throughout the world. Advantages are cited as reduced rate of cesareans, shorter time from induction to birth and, particularly in developing countries, lower cost, oral, vaginal or rectal administration, and stability without refrigeration. Disadvantages are uterine hyperstimulation and, in rare instances, uterine rupture and death. Mothers should be informed of both the risks and the possible benefits of misoprostol. Further research with large samples is necessary to determine whether the risks outweigh any possible benefits.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: labor induction; misoprostol

Document Type: Miscellaneous

Affiliations: MARY LOU MOORE is an associate professor in the Department of Obstetrics and Gynecology at the Wake Forest University School of Medicine in Winston-Salem, North Carolina.

Publication date: July 1, 2002

More about this publication?
  • The Journal of Perinatal Education is no longer available to subscribers on Ingenta Connect. Please go to http://connect.springerpub.com/content/sgrjpe to access your online subscription to The Journal of Perinatal Education.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more